Seres Therapeutics (NASDAQ:MCRB) Stock Passes Above 50-Day Moving Average - Time to Sell?

Key Points

• Seres Therapeutics' stock price has recently crossed above its 50-day moving average of $16.35, achieving a high of $18.78 before last trading at $17.45.
• The company reported a quarterly loss of ($2.27) EPS, which beat analysts' expectations of ($2.72) EPS.
• Institutional investors, including Millennium Management LLC and Invesco Ltd., have shown significant interest, with hedge funds and institutions owning 59.34% of the company's stock.

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report)'s stock price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $16.35 and traded as high as $18.78. Seres Therapeutics shares last traded at $17.45, with a volume of 205,420 shares changing hands.

Seres Therapeutics Price Performance

The company has a market cap of $152.77 million, a P/E ratio of -3.79 and a beta of 0.15. The company's 50-day moving average price is $16.35 and its 200-day moving average price is $12.30.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($2.27) earnings per share for the quarter, topping the consensus estimate of ($2.72) by $0.45. On average, equities research analysts predict that Seres Therapeutics, Inc. will post -0.38 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Marshall Wace LLP bought a new position in Seres Therapeutics in the 2nd quarter worth about $1,016,000. XTX Topco Ltd purchased a new stake in Seres Therapeutics in the second quarter worth $249,000. Goldman Sachs Group Inc. grew its stake in Seres Therapeutics by 40.9% in the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 21,679 shares during the last quarter. Invesco Ltd. boosted its holdings in Seres Therapeutics by 193.2% in the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock worth $96,000 after acquiring an additional 89,995 shares in the last quarter. Finally, SBI Securities Co. Ltd. boosted its position in Seres Therapeutics by 221.8% in the first quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company's stock valued at $49,000 after buying an additional 48,013 shares during the last quarter. 59.34% of the stock is owned by hedge funds and other institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.